Advice
Medicine withdrawn
Voxelotor (Oxbryta) was withdrawn in September 2024 pending a review of the benefits and risks.
Medicine details
- Medicine name:
- voxelotor (Oxbryta)
- SMC ID:
- SMC2626
- Indication:
Treatment of haemolytic anaemia due to sickle cell disease (SCD) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Withdrawn
- Date advice published
- 10 June 2024
Additional notes
Voxelotor (Oxbryta) was withdrawn in September 2024.